HKSE
3.14HKD
-0.17 (-5.14%)
We have scored 5 news catalysts on Antengene Corporation Limited (6996.HK) over the past 12 months. The biggest single-day move next to one of them came Oct 9, 2026, when 6996.HK closed −5.0%: “Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026”. Coverage across the window leans positive (average ticker sentiment +0.76). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.1B
P/E
—
EPS
—
Beta
0.37
52W range
2.76-6.41
Day range
—
Open
—
Prev close
—
Volume
763.5K
Avg volume
1.4M
Dividend
0.00
IPO
2020-11-20
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Antengene Corporation Limited — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for 6996.HK: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.
